$328 Million is the total value of Opaleye Management Inc.'s 43 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -60,000 | -100.0% | -0.11% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -25,200 | -100.0% | -0.12% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -180,000 | -100.0% | -0.19% | – |
| ESTA | Exit | ESTABLISHMENT LABS HLDGS INC | $0 | – | -50,000 | -100.0% | -0.33% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -115,000 | -100.0% | -0.62% | – |
| LQDA | Exit | LIQUIDIA TECHNOLOGIES INC | $0 | – | -225,000 | -100.0% | -0.71% | – |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.73% | – |
| SWAV | Exit | SHOCKWAVE MED INC | $0 | – | -92,100 | -100.0% | -0.85% | – |
| ACOR | Exit | ACORDA PHARMACEUTICALS | $0 | – | -265,000 | -100.0% | -0.98% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -1.09% | – |
| ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -560,000 | -100.0% | -1.14% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -205,000 | -100.0% | -1.28% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -185,000 | -100.0% | -1.35% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -400,000 | -100.0% | -1.50% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -2.02% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -105,000 | -100.0% | -2.13% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -1,825,000 | -100.0% | -2.58% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -440,000 | -100.0% | -2.85% | – |
| CMTA | Exit | CLEMENTIA PHARMACEUTICALS INC | $0 | – | -400,130 | -100.0% | -2.89% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -95,000 | -100.0% | -3.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 42 | Q2 2024 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 30 | Q2 2024 | 3.6% |
| OCULAR THERAPEUTIX INC | 27 | Q2 2024 | 17.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| ETON PHARMACEUTICALS INC | 23 | Q2 2024 | 5.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| TG THERAPEUTICS INC | 20 | Q2 2024 | 10.1% |
| CRINETICS PHARMACEUTICALS INC | 20 | Q1 2024 | 5.6% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| iBio, Inc. | April 09, 2024 | 650,000 | 7.6% |
| OCULAR THERAPEUTIX, INC | February 14, 2024 | 6,070,000 | 5.5% |
| SANUWAVE Health, Inc. | February 14, 2024 | 115,493,554 | 9.1% |
| HARROW, INC. | February 09, 2024 | 3,820,000 | 10.9% |
| Jounce Therapeutics, Inc.Sold out | February 09, 2024 | 0 | 0.0% |
| Tracon Pharmaceuticals, Inc. | February 09, 2024 | 10 | 0.0% |
| Context Therapeutics Inc. | January 05, 2024 | 820,000 | 5.1% |
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-09-23 |
| 4 | 2024-09-19 |
| SC 13G/A | 2024-09-18 |
| 3 | 2024-09-12 |
| 4 | 2024-09-12 |
| 4 | 2024-09-12 |
| SC 13G/A | 2024-09-12 |
| 4 | 2024-09-10 |
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.